Passive immunity in the prevention of rabies

The Lancet Infectious Diseases

Volumn 12, Issue 5, 2012, Pages 397-407

  Both, Leonard ^a,b   Banyard, Ashley C ^b   van Dolleweerd, Craig ^a   Horton, Daniel L ^b,c   Ma, Julian K C ^a   Fooks, Anthony R ^b,d  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b VETERINARY LABORATORIES AGENCY   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CL 184; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; RABIES IMMUNOGLOBULIN; RABIES VACCINE; UNCLASSIFIED DRUG;

ANTIBODY TITER; DRUG COST; HUMAN; HUMORAL IMMUNITY; IMMUNOPROPHYLAXIS; INFECTION PREVENTION; INFECTION RISK; NONHUMAN; NUCLEOTIDE SEQUENCE; PASSIVE IMMUNIZATION; PHYLOGENETIC TREE; POLYCLONAL SERUM; PRIORITY JOURNAL; RABIES; RABIES VIRUS; REVIEW; SERUM; VACCINATION; VIRUS INHIBITION; VIRUS NEUTRALIZATION; VIRUS TRANSMISSION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS; RABIES;

EID: 84860266537     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(11)70340-1     Document Type: Review

References (154)

1. Behring EA, Kitasato S Ueber das Zustandekommen der Diptherie-Immunität und der Tetanus-Immunität bei Thieren. Deutch Med Woch 1890, 49:1113-1114.
2. Strohl WR, Knight DM Discovery and development of biopharmaceuticals: current issues. Curr Opin Biotechnol 2009, 20:668-672.
3. Good RA, Lorenz E Historic aspects of intravenous immunoglobulin therapy. Cancer 1991, 68:1415-1421.
4. Casadevall A, Dadachova E, Pirofski LA Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2004, 2:695-703.
5. Marasco WA, Sui J The growth and potential of human antiviral monoclonal antibody therapeutics. Nat Biotechnol 2007, 25:1421-1434.
6. Saylor C, Dadachova E, Casadevall A Monoclonal antibody-based therapies for microbial diseases. Vaccine 2009, 27:38-46.
7. Knobel DL, Cleaveland S, Coleman PG, et al. Re-evaluating the burden of rabies in Africa and Asia. Bull World Health Organ 2005, 83:360-368.
8. Rupprecht CE, Gibbons RV Clinical practice. Prophylaxis against rabies. N Engl J Med 2004, 351:2626-2635.
9. Hemachudha T, Laothamatas J, Rupprecht CE Human rabies: a disease of complex neuropathogenetic mechanisms and diagnostic challenges. Lancet Neurol 2002, 1:101-109.
10. Warrell DA The clinical picture of rabies in man. Trans R Soc Trop Med Hyg 1976, 70:188-195.
11. Warrell DA, Davidson NM, Pope HM, et al. Pathophysiologic studies in human rabies. Am J Med 1976, 60:180-190.
12. Marston DA, Horton DL, Ngeleja C, et al. Ikoma lyssavirus, highly divergent novel lyssavirus in an African civet. Emerg Infect Dis (in press). DOI:10.3201/eid1804.111553.
13. Kuzmin IV, Niezgoda M, Franka R, et al. Possible emergence of West Caucasian bat virus in Africa. Emerg Infect Dis 2008, 14:1887-1889.
14. Wright E, Hayman DT, Vaughan A, et al. Virus neutralising activity of African fruit bat (Eidolon helvum) sera against emerging lyssaviruses. Virology 2010, 408:183-189.
15. Kuzmin IV, Mayer AE, Niezgoda M, et al. Shimoni bat virus, a new representative of the Lyssavirus genus. Virus Res 2010, 149:197-210.
16. Paweska JT, Blumberg LH, Liebenberg C, et al. Fatal human infection with rabies-related Duvenhage virus, South Africa. Emerg Infect Dis 2006, 12:1965-1967.
17. Van Thiel PP, van den Hoek JA, Eftimov F, et al. Fatal case of human rabies (Duvenhage virus) from a bat in Kenya: The Netherlands, December 2007. Euro Surveill 2008, 13:8007.
18. van Thiel PP, de Bie RM, Eftimov F, et al. Fatal human rabies due to Duvenhage virus from a bat in Kenya: failure of treatment with coma-induction, ketamine, and antiviral drugs. PLoS Negl Trop Dis 2009, 3:e428.
19. Johnson N, Un H, Fooks AR, et al. Rabies epidemiology and control in Turkey: past and present. Epidemiol Infect 2010, 138:305-312.
20. Amengual B, Whitby JE, King A, Cobo JS, Bourhy H Evolution of European bat lyssaviruses. J Gen Virol 1997, 78:2319-2328.
21. Banyard AC, Johnson N, Voller K, et al. Repeated detection of European bat lyssavirus type 2 in dead bats found at a single roost site in the UK. Arch Virol 2009, 154:1847-1850.
22. Fooks AR, McElhinney LM, Pounder DJ, et al. Case report: isolation of a European bat lyssavirus type 2a from a fatal human case of rabies encephalitis. J Med Virol 2003, 71:281-289.
23. Fooks AR, Brookes SM, Johnson N, McElhinney LM, Hutson AM European bat lyssaviruses: an emerging zoonosis. Epidemiol Infect 2003, 131:1029-1039.
24. Johnson N, Vos A, Freuling C, Tordo N, Fooks AR, Müller T Human rabies due to lyssavirus infection of bat origin. Vet Microbiol 2010, 142:151-159.
25. Warrilow D Australian bat lyssavirus: a recently discovered new rhabdovirus. Curr Top Microbiol Immunol 2005, 292:25-44.
26. Hanna JN, Carney IK, Smith GA, et al. Australian bat lyssavirus infection: a second human case, with a long incubation period. Med J Aust 2000, 172:597-599.
27. Babès V, Lepp M Recherches sur la vaccination antirabique. Ann Inst Pasteur 1889, 3:384.
28. Habel K Antiserum in the prophylaxis of rabies. Bull World Health Organ 1954, 10:781-788.
29. Koprowski H, van der Scheer J, Black J Use of hyperimmune anti-rabies serum concentrates in experimental rabies. Am J Med 1950, 8:412-420.
30. Atanasiu P, Bahmanyar M, Baltazard M, et al. Rabies neutralizing antibody response to different schedules of serum and vaccine inoculations in non-exposed persons. Bull World Health Organ 1956, 14:593-611.
31. Habel K Rabies prophylaxis in man. Public Health Rep 1957, 72:667-673.
32. Baltazard M, Bahmanyar M Field trials with rabies vaccine on persons bitten by rabid wolves. Bull World Health Organ 1955, 13:747-772.
33. Habel K, Koprowski H Laboratory data supporting the clinical trial of anti-rabies serum in persons bitten by a rabid wolf. Bull World Health Organ 1955, 13:773-779.
34. Atanasiu P, Bahmanyar M, Baltazard M, et al. Rabies neutralizing antibody response to different schedules of serum and vaccine inoculations in non-exposed persons-II. Bull World Health Organ 1957, 17:911-932.
35. Atanasiu P, Cannon DA, Dean DJ, et al. Rabies neutralizing antibody response to different schedules of serum and vaccine inoculations in non-exposed persons-III. Bull World Health Organ 1961, 25:103-114.
36. Atanasiu P, Dean DJ, Habel K, et al. Rabies neutralizing antibody response to different schedules of serum and vaccine inoculations in non-exposed persons-IV. Bull World Health Organ 1967, 36:361-365.
37. Habel H Rabies antiserum interference with antigenicity of vaccine in mice. Bull World Health Organ 1957, 17:933-936.
38. Wiktor TJ, Lerner RA, Koprowski H Inhibitory effect of passive antibody on active immunity induced against rabies by vaccination. Bull World Health Organ 1971, 45:747-753.
39. Fooks AR Rabies remains a 'neglected disease'. Euro Surveill 2005, 10:1-2.
40. Schnell MJ, McGettigan JP, Wirblich C, Papaneri A The cell biology of rabies virus: using stealth to reach the brain. Nat Rev Microbiol 2010, 8:51-61.
41. Cleaveland S, Fèvre EM, Kaare M, Coleman PG Estimating human rabies mortality in the United Republic of Tanzania from dog bite injuries. Bull World Health Organ 2002, 80:304-310.
42. Mallewa M, Fooks AR, Banda D, et al. Rabies encephalitis in malaria-endemic area, Malawi, Africa. Emerg Infect Dis 2007, 13:136-139.
43. Warrell MJ The challenge to provide affordable rabies post-exposure treatment. Vaccine 2003, 21:706-709.
44. Kaplan MM, Cohen D, Koprowski H, Dean D, Ferrigan L Studies on the local treatment of wounds for the prevention of rabies. Bull World Health Organ 1962, 26:765-775.
45. Rupprecht CE, Hanlon CA, Hemachudha T Rabies re-examined. Lancet Infect Dis 2002, 2:327-343.
46. Jackson AC, Warrell MJ, Rupprecht CE, et al. Management of rabies in humans. Clin Infect Dis 2003, 36:60-63.
47. Wilde H, Hemachudha T, Jackson AC Viewpoint: management of human rabies. Trans R Soc Trop Med Hyg 2008, 102:979-982.
48. Smith JS, Fishbein DB, Rupprecht CE, Clark K Unexplained rabies in three immigrants in the United States. A virologic investigation. N Engl J Med 1991, 324:205-211.
49. Manning SE, Rupprecht CE, Fishbein D, et al. Human rabies prevention-United States, 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2008, 57:1-28.
50. Rupprecht CE, Briggs D, Brown CM, et al. Evidence for a 4-dose vaccine schedule for human rabies post-exposure prophylaxis in previously non-vaccinated individuals. Vaccine 2009, 27:7141-7148.
51. Saesow N, Chaiwatanarat T, Mitmoonpitak C, Wilde H Diffusion and fate of intramuscularly injected human rabies immune globulin. Acta Trop 2000, 76:289-292.
52. Dean DJ, Baer GM, Thompson WR Studies on the local treatment of rabies-infected wounds. Bull World Health Organ 1963, 28:477-486.
53. Wilde H, Sirikawin S, Sabcharoen A, et al. Failure of postexposure treatment of rabies in children. Clin Infect Dis 1996, 22:228-232.
54. Lang J, Simanjuntak GH, Soerjosembodo S, Koesharyono C Suppressant effect of human or equine rabies immunoglobulins on the immunogenicity of post-exposure rabies vaccination under the 2-1-1 regimen: a field trial in Indonesia. MAS054 Clinical Investigator Group. Bull World Health Organ 1998, 76:491-495.
55. Mertz GJ, Nelson KE, Vithayasai V, et al. Antibody responses to human diploid cell vaccine for rabies with and without human rabies immune globulin. J Infect Dis 1982, 145:720-727.
56. Cabasso VJ, Loofbourow JC, Roby RE, Anuskiewicz W Rabies immune globulin of human origin: preparation and dosage determination in non-exposed volunteer subjects. Bull World Health Organ 1971, 45:303-315.
57. Khawplod P, Wilde H, Chomchey P, et al. What is an acceptable delay in rabies immune globulin administration when vaccine alone had been given previously?. Vaccine 1996, 14:389-391.
58. Shantavasinkul P, Tantawichien T, Wacharapluesadee S, et al. Failure of rabies postexposure prophylaxis in patients presenting with unusual manifestations. Clin Infect Dis 2010, 50:77-79.
59. Basgoz N, Frosch M Case 21-1998: a 32-year-old woman with pharyngeal spasms and paresthesias after a dog bite. N Engl J Med 1998, 339:105-112.
60. Hattwick MA, Corey L, Creech WB Clinical use of human globulin immune to rabies virus. J Infect Dis 1976, 133:266-272.
61. Hemachudha T, Sunsaneewitayakul B, Mitrabhakdi E, et al. Paralytic complications following intravenous rabies immune globulin treatment in a patient with furious rabies. Int J Infect Dis 2003, 7:76-77.
62. Prabhakar BS, Nathanson N Acute rabies death mediated by antibody. Nature 1981, 290:590-591.
63. Willoughby RE " Early death" and the contraindication of vaccine during treatment of rabies. Vaccine 2009, 27:7173-7177.
64. Sikes RK, Cleary WF, Koprowski H, Wiktor TJ, Kaplan MM Effective protection of monkeys against death from street virus by post-exposure administration of tissue-culture rabies vaccine. Bull World Health Organ 1971, 1:1-11.
65. King AA, Sands JJ, Porterfield JS Antibody-mediated enhancement of rabies virus infection in a mouse macrophage cell line. J Gen Virol 1984, 6:1091-1093.
66. Halstead SB, O'Rourke EJ Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J Exp Med 1977, 146:201-217.
67. Paul SM Therapeutic antibodies for brain disorders. Sci Transl Med 2011, 84:84ps20.
68. Pardridge WM Drug and gene targeting to the brain with molecular Trojan horses. Nat Rev Drug Discov 2002, 2:131-139.
69. Yu YJ, Zhang Y, Kenrick M, et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med 2011, 84:84ra44.
70. Willoughby RE, Tieves KS, Hoffman GM, et al. Survival after treatment of rabies with induction of coma. N Engl J Med 2005, 352:2508-2514.
71. Bourhy H, Dautry-Varsat A, Hotez PJ, Salomon J Rabies, still neglected after 125 years of vaccination. PLoS Negl Trop Dis 2010, 4:e839.
72. Warrell M Rabies and African bat lyssavirus encephalitis and its prevention. Int J Antimicrob Agents 2010, 36:47-52.
73. Rabies fact sheet No 99 WHO, (accessed Dec 10, 2010). http://www.who.int/mediacentre/factsheets/fs099/en/.
74. Hampson K, Dobson A, Kaare M, et al. Rabies exposures, post-exposure prophylaxis and deaths in a region of endemic canine rabies. PLoS Negl Trop Dis 2008, 2:e339.
75. Fooks AR Rabies-the need for a 'one medicine' approach. Vet Rec 2007, 161:289-290.
76. Sudarshan MK, Mahendra BJ, Madhusudana SN, et al. An epidemiological study of animal bites in India: results of a WHO sponsored national multi-centric rabies survey. J Commun Dis 2006, 38:32-39.
77. Hu R, Tang Q, Tang J, Fooks AR Rabies in China: an update. Vector Borne Zoonotic Dis 2009, 9:1-12.
78. Song M, Tang Q, Wang DM, et al. Epidemiological investigations of human rabies in China. BMC Infect Dis 2009, 9:210.
79. Si H, Guo ZM, Hao YT, et al. Rabies trend in China (1990-2007) and post-exposure prophylaxis in the Guangdong province. BMC Infect Dis 2008, 8:113.
80. Fang LX, Ping F, Ping du Y, Hui BG, Yan YX Socioeconomic status is a critical risk factor for human rabies post-exposure prophylaxis. Vaccine 2010, 28:6847-6851.
81. Belotto A, Leanes LF, Schneider MC, Tamayo H, Correa E Overview of rabies in the Americas. Virus Res 2005, 111:5-12.
82. Krebs JW, Long-Marin SC, Childs JE Causes, costs, and estimates of rabies postexposure prophylaxis treatments in the United States. J Public Health Manag Pract 1998, 4:56-62.
83. Christian KA, Blanton JD, Auslander M, Rupprecht CE Epidemiology of rabies post-exposure prophylaxis-United States of America, 2006-2008. Vaccine 2009, 27:7156-7161.
84. Müller T, Dietzschold B, Ertl H, et al. Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans. PLoS Negl Trop Dis 2009, 3:e542.
85. Hossain M, Bulbul T, Ahmed K, et al. Five-year (January 2004-December 2008) surveillance on animal bite and rabies vaccine utilization in the Infectious Disease Hospital, Dhaka, Bangladesh. Vaccine 2011, 29:1036-1040.
86. Halpin K, Hyatt AD, Plowright RK, et al. Emerging viruses: coming in on a wrinkled wing and a prayer. Clin Infect Dis 2007, 44:711-717.
87. Schneider MC, Romijn PC, Uieda W, et al. Rabies transmitted by vampire bats to humans: an emerging zoonotic disease in Latin America?. Rev Panam Salud Publica 2009, 25:260-269.
88. Thisyakorn U, Pancharoen C, Ruxrungtham K, et al. Safety and immunogenicity of preexposure rabies vaccination in children infected with human immunodeficiency virus type 1. Clin Infect Dis 2000, 30:218.
89. Tantawichien T, Jaijaroensup W, Khawplod P, Sitprija V Failure of multiple-site intradermal postexposure rabies vaccination in patients with human immunodeficiency virus with low CD4+ T lymphocyte counts. Clin Infect Dis 2001, 33:122-124.
90. Jaijaroensup W, Tantawichien T, Khawplod P, Tepsumethanon S, Wilde H Postexposure rabies vaccination in patients infected with human immunodeficiency virus. Clin Infect Dis 1999, 28:913-914.
91. Human rabies prevention-United States, 2008. Recommendations of the Advisory Committee on Immunization Practices Centers for Disease Control and Prevention, (accessed March 3, 2010). http://www.cdc.gov/mmwr/PDF/rr/rr5703.pdf.
92. Mattner F, Bitz F, Goedecke M, et al. Adverse effects of rabies pre- and postexposure prophylaxis in 290 health-care-workers exposed to a rabies infected organ donor or transplant recipients. Infection 2007, 35:219-224.
93. Noah DL, Smith MG, Gotthardt JC, Krebs JW, Green D, Childs JE Mass human exposure to rabies in New Hampshire: exposures, treatment, and cost. Am J Public Health 1996, 86:1149-1151.
94. Mass treatment of humans exposed to rabies - New Hampshire, 1994. MMWR Morb Mortal Wkly Rep 1995, 44:484-486. Centers for Disease Control and Prevention.
95. Mendes WdS, Silva AA, Neiva RF, et al. An outbreak of bat-transmitted human rabies in a village in the Brazilian Amazon. Rev Saude Publica 2009, 43:1075-1077.
96. Quiambao BP, Dy-Tioco HZ, Dizon RM, Crisostomo ME, Teuwen DE Rabies post-exposure prophylaxis with purified equine rabies immunoglobulin: one-year follow-up of patients with laboratory-confirmed category III rabies exposure in the Philippines. Vaccine 2009, 27:7162-7166.
97. Ertl HC Novel vaccines to human rabies. PLoS Negl Trop Dis 2009, 9:e515.
98. Hanlon CA, Niezgoda M, Morrill PA, Rupprecht CE The incurable wound revisited: progress in human rabies prevention?. Vaccine 2001, 19:2273-2279.
99. Dodet B The fight against rabies in Africa: from recognition to action. Vaccine 2009, 27:5027-5032. for the Africa Rabies Bureau (AfroREB).
100. Satpathy DM, Sahu T, Behera TR Equine rabies immunoglobulin: a study on its clinical safety. J Indian Med Assoc 2005, 103:241-242. 238.
101. Ly S, Buchy P, Heng NY, et al. Rabies situation in Cambodia. PLoS Negl Trop Dis 2009, 3:e511.
102. Kramer RA, Marissen WE, Goudsmit J, et al. The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries. Eur J Immunol 2005, 35:2131-2145.
103. Arai YT, Kuzmin IV, Kameoka Y, Botvinkin AD New lyssavirus genotype from the lesser mouse-eared bat (Myotis blythi), Kyrghyzstan. Emerg Infect Dis 2003, 9:333-337.
104. Kuzmin IV, Orciari LA, Arai YT, et al. Bat lyssaviruses (Aravan and Khujand) from Central Asia: phylogenetic relationships according to N, P and G gene sequences. Virus Res 2003, 97:65-79.
105. Botvinkin AD, Poleschuk EM, Kuzmin IV, et al. Novel lyssaviruses isolated from bats in Russia. Emerg Infect Dis 2003, 9:1623-1625.
106. Hanlon CA, Kuzmin IV, Blanton JD, Weldon WC, Manangan JS, Rupprecht CE Efficacy of rabies biologics against new lyssaviruses from Eurasia. Virus Res 2005, 111:44-54.
107. Horton DL, McElhinney LM, Marston DA, et al. Quantifying antigenic relationships among the lyssaviruses. J Virol 2010, 84:11841-11848.
108. Badrane H, Bahloul C, Perrin P, Tordo N Evidence of two Lyssavirus phylogroups with distinct pathogenicity and immunogenicity. J Virol 2001, 75:3268-3276.
109. Irie T, Kawai A Studies on the different conditions for rabies virus neutralization by monoclonal antibodies #1-46-12 and #7-1-9. J Gen Virol 2002, 12:3045-3053.
110. Flamand A, Raux H, Gaudin Y, Ruigrok RW Mechanisms of rabies virus neutralization. Virology 1993, 1:302-313.
111. Fernandes A, Kaundinya JO, Daftary G, Saxena L, Banerjee S, Pattnaik P Chromatographic purification of equine immunoglobulin G F(ab)2 from plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2008, 876:109-115.
112. Saylor C, Dadachova E, Casadevall A Monoclonal antibody-based therapies for microbial diseases. Vaccine 2009, 27:38-46.
113. Bakker AB, Python C, Kissling CJ, et al. First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. Vaccine 2008, 26:5922-5927.
114. Wiktor TJ, Koprowski H Monoclonal antibodies against rabies virus produced by somatic cell hybridization: detection of antigenic variants. Proc Natl Acad Sci USA 1978, 75:3938-3942.
115. Schumacher CL, Dietzschold B, Ertl HC, Niu HS, Rupprecht CE, Koprowski H Use of mouse anti-rabies monoclonal antibodies in postexposure treatment of rabies. J Clin Invest 1989, 3:971-975.
116. Dietzschold B, Gore M, Casali P, et al. Biological characterization of human monoclonal antibodies to rabies virus. J Virol 1990, 64:3087-3090.
117. Li J, Zhu Z Research and development of next generation of antibody-based therapeutics. Acta Pharmacol Sin 2010, 31:1198-1207.
118. Chan AC, Carter PJ Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010, 10:301-316.
119. Nelson AL, Dhimolea E, Reichert JM Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 2010, 9:767-774.
120. Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 2010, 9:325-338.
121. ter Meulen J, van den Brink EN, Poon LL, et al. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med 2006, 3:e237.
122. Goudsmit J, Marissen WE, Weldon WC, et al. Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin. J Infect Dis 2006, 193:796-801.
123. Nowakowski A, Wang C, Powers DB, et al. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci USA 2002, 99:11346-11350.
124. Dietzschold B, Kao M, Zheng YM, et al. Delineation of putative mechanisms involved in antibody-mediated clearance of rabies virus from the central nervous system. Proc Natl Acad Sci USA 1992, 89:7252-7256.
125. Ko K, Tekoah Y, Rudd PM, et al. Function and glycosylation of plant-derived antiviral monoclonal antibody. Proc Natl Acad Sci USA 2003, 100:8013-8018.
126. Girard LS, Fabis MJ, Bastin M, Courtois D, Pétiard V, Koprowski H Expression of a human anti-rabies virus monoclonal antibody in tobacco cell culture. Biochem Biophys Res Commun 2006, 345:602-607.
127. Enssle K, Kurrle R, Köhler R, et al. A rabies-specific human monoclonal antibody that protects mice against lethal rabies. Hybridoma 1991, 10:547-556.
128. Champion JM, Kean RB, Rupprecht CE, et al. The development of monoclonal human rabies virus-neutralizing antibodies as a substitute for pooled human immune globulin in the prophylactic treatment of rabies virus exposure. J Immunol Methods 2000, 235:81-90.
129. Hanlon CA, DeMattos CA, DeMattos CC, et al. Experimental utility of rabies virus-neutralizing human monoclonal antibodies in post-exposure prophylaxis. Vaccine 2001, 19:3834-3842.
130. Prosniak M, Faber M, Hanlon CA, Rupprecht CE, Hooper DC, Dietzschold B Development of a cocktail of recombinant-expressed human rabies virus-neutralizing monoclonal antibodies for postexposure prophylaxis of rabies. J Infect Dis 2003, 188:53-56.
131. Bakker AB, Marissen WE, Kramer RA, et al. Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants. J Virol 2005, 79:9062-9068.
132. Marissen WE, Kramer RA, Rice AB, et al. Novel rabies virus-neutralizing epitope recognized by human monoclonal antibody: fine mapping and escape mutant analysis. J Virol 2005, 79:4672-4678.
133. De Kruif J, Bakker AB, Marissen WE, et al. A human monoclonal antibody cocktail as a novel component of rabies postexposure prophylaxis. Annu Rev Med 2007, 58:359-368.
134. Muhamuda K, Madhusudana SN, Ravi V Use of neutralizing murine monoclonal antibodies to rabies glycoprotein in passive immunotherapy against rabies. Hum Vaccin 2007, 3:192-195.
135. Sloan SE, Hanlon C, Weldon W, et al. Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates. Vaccine 2007, 25:2800-2810.
136. Wang Y, Rowley KJ, Booth BJ, Sloan SE, Ambrosino DM, Babcock GJ G glycoprotein amino acid residues required for human monoclonal antibody RAB1 neutralization are conserved in rabies virus street isolates. Antiviral Res 2011, 2:187-194.
137. Hooper DC, Phares TW, Fabis MJ, Roy A The production of antibody by invading B cells is required for the clearance of rabies virus from the central nervous system. PLoS Negl Trop Dis 2009, 3:e535.
138. Bendandi M, Marillonnet S, Kandzia R, et al. Rapid, high-yield production in plants of individualized idiotype vaccines for non-Hodgkin's lymphoma. Ann Oncol 2010, 12:2420-2427.
139. Bakker H, Rouwendal GJ, Karnoup AS, et al. An antibody produced in tobacco expressing a hybrid beta-1,4-galactosyltransferase is essentially devoid of plant carbohydrate epitopes. Proc Natl Acad Sci USA 2006, 20:7577-7582.
140. Cox KM, Sterling JD, Regan JT, et al. Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor. Nat Biotechnol 2006, 12:1591-1597.
141. Human monoclonal antibodies for PEP Global Alliance for Rabies Control, (accessed March 3, 2012). http://www.rabiescontrol.net/news/news-archive/human-monoclonals.html.
142. Office of Communications: International collaboration takes aim at rabies University of Massachusetts Medical School, (accessed March 3, 2012). http://www.umassmed.edu/Content.aspx?id=33562.
143. Beck A, Wurch T, Bailly C, Corvaia N Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 2010, 10:345-352.
144. Ma JK, Drake PM, Chargelegue D, Obregon P, Prada A Antibody processing and engineering in plants, and new strategies for vaccine production. Vaccine 2005, 23:1814-1818.
145. Armbruster C, Stiegler GM, Vcelar BA, et al. Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12. J Antimicrob Chemother 2004, 54:915-920.
146. Cleaveland S, Kaare M, Knobel D, Laurenson MK Canine vaccination - providing broader benefits for disease control. Vet Microbiol 2006, 117:43-50.
147. Tao XY, Tang Q, Li H, et al. Molecular epidemiology of rabies in southern People's Republic of China. Emerg Infect Dis 2009, 15:1192-1198.
148. Zhang YZ, Xiong CL, Xiao DL, et al. Human rabies in China. Emerg Infect Dis 2005, 11:1983-1984.
149. Tang X, Luo M, Zhang S, Fooks AR, Hu R, Tu C Pivotal role of dogs in rabies transmission, China. Emerg Infect Dis 2005, 11:1970-1972.
150. Lembo T, Attlan M, Bourhy H, et al. Renewed global partnerships and redesigned roadmaps for rabies prevention and control. Vet Med Int 2011, 2011:923149.
151. Fooks AR, Johnson N, Brookes SM, Parsons G, McElhinney LM Risk factors associated with travel to rabies endemic countries. J Appl Microbiol 2003, 94:31-36.
152. Dodet B, Goswami A, Gunasekera A, et al. Rabies awareness in eight Asian countries. Vaccine 2008, 26:6344-6348.
153. Briggs D, Hanlon CA World Rabies Day: focusing attention on a neglected disease. Vet Rec 2007, 161:288-289.
154. Dodet B An important date in rabies history. Vaccine 2007, 25:8647-8650. for the Asian Rabies Expert Bureau (AREB).